Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer

Published:2014-07-25 Issue:4 Volume:74 Page:681-690
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Macedo-Pérez Eleazar Omar,Morales-Oyarvide Vicente,Mendoza-García Víctor Osvaldo,Dorantes-Gallareta Yuzmiren,Flores-Estrada Diana,Arrieta Oscar

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-014-2522-9.pdf

Reference32 articles.

1. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

2. INEGI 2013. Estadísticas de mortalidad en México

3. Travis WD (2011) Classification of lung cancer. Semin Roentgenol 46:178–186

4. SEER Stat Fact Sheets: Lung and Bronchus Cancer (May 1 2014): http://seer.cancer.gov/statfacts/html/lungb.html

5. Arrieta O, Guzmán-de Alba E, Alba-López LF (2013) Consenso Nacional de Diagnóstico y tratamiento de cancer pulmonar de células no pequeñas. Rev Invest Clin 65(Supl. 1):s5–s84

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer;Heliyon;2024-02

2. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report;Annals of Palliative Medicine;2022-09

3. Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non‐small cell lung cancer: A meta‐analysis;Thoracic Cancer;2021-10-07

4. Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study;Technology in Cancer Research & Treatment;2021-01

5. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer;JAMA Oncology;2020-06-01